SABCS 2022 | Sequencing agents for HER2+ metastatic breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses sequencing agents for HER2+ metastatic breast cancer. The Phase III DESTINY-Breast02 (NCT03523585) and the Phase III DESTINY-Breast03 (NCT03529110) demonstrated has a survival advantage with trastuzumab deruxtecan (T-DXd) in both the second-line and later lines setting. However, in the second-line, T-DXd demonstrated outstanding activity, demonstrating a median 28 month progression-free survival (PFS) compared to 18 months in later lines. For a subset of patients which are yet to be identified, however, Trastuzumab emtansine (TDM-1) fared better in the second-line. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.